Clinical Trial Update: A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial compares hypofractionated proton therapy to IMRT for recurrent, oligometastatic prostate cancer and is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING